慢性心力衰竭的器械治疗:JACC最新综述
本文综述了慢性心力衰竭及相关合并症的器械治疗现状与未来前景,并梳理了推动当前及未来创新的监管环境。文章指出,自2013年FDA发布早期可行性及首次人体研究指南、2016年美国国会授权突破性器械计划以来,寻求突破性 designation 途径批准的HF器械数量增加,促进了器械治疗研发与评估的快速 uptake。
要点
- FDA 2013年指南和2016年突破性器械计划推动了HF器械创新与评估。
- 综述涵盖慢性HF及相关合并症的当前与未来器械治疗及监管环境。
核心结论
- 过去7年HF器械治疗的监管格局发生重大转变,鼓励了器械创新并加速了HF器械的研发与评估。
主要发现
- 2013年FDA发布早期可行性及首次人体研究指南,鼓励器械创新。
- 2016年美国国会授权突破性器械计划,以加速美国人获得用于诊断和治疗严重疾病(如HF)的创新器械。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The regulatory landscape for device-based heart failure (HF) therapies has seen a major shift in the last 7 years. In 2013, the U.S. Food and Drug Administration released guidance for early feasibility and first-in-human studies, thereby encouraging device innovation, and in 2016 the U.S. Congress authorized the Breakthrough Devices Program to expedite access for Americans to innovative devices indicated for diagnosis and treatment of serious illnesses, such as HF. Since December 2016, there has been an increase in the number of HF devices for which manufacturers are seeking approval through the breakthrough designation pathway. This has led to a rapid uptake in the development and evaluation of device-based HF therapies. This article reviews the current and future landscape of device therapies for chronic HF and associated comorbidities and the regulatory environment that is driving current and future innovation.
引用
- Fudim M, Abraham WT, von Bardeleben RS, et al. Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021. PMID: 34446165. doi:10.1016/j.jacc.2021.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。